Comparative Study for Clinical Outcomes of Triple-Positive and Triple-Negative Breast Cancer: Long-term Results in 161 Patients Followed in a Single Center
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Triple negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer. However, we have often experienced that triple positive breast cancer (TPBC) shows more aggressive clinical features than TNBC. In this retrospective study, we aimed to examine the differences in clinical courses between TNBC and TPBC. Methods: Using medical records and clinical data, we selected patients with breast cancer who met the criteria for the two groups, TNBC and TPBC, based on the expression or absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). We then compared these groups with respect to clinical and pathological variables, such as patient age at diagnosis, TNM stage, number of tumors, involvement of resection margin, operation methods, histologic grade (HG), nuclear grade (NG), and lymphatic invasion (LI). We also compared the disease-free (DFS) and overall survival (OS) outcomes between the groups. Results: Seventy patients with TNBC and 91 with TPBC were identified among a total of 628 patients. In univariate analysis, TPBC was significantly more frequently associated with lower HG (p=0.001), lower NG (p=0.003), LI (p=0.001), and a Ki-67 index ≤20% (p<0.001). In multivariate analysis, a lower Ki-67 index (p=0.031) and LI (p=0.022) were identified as significant and independent factors contributing to DFS. In a survival analysis over time, the TPBC showed a worse OS than TNBC 5 years post-treatment for breast cancer. Consequently, the TPBC group had definite worse 10-year DFS (p=0.012) and showed relatively lower OS rate (p=0.058), than the TNBC group. Conclusion: Our results demonstrate considerable differences in long-term post-treatment survival of patients with TPBC and TNBC. Further studies to determine the proper management of both types of breast cancer and an accurate prognostic evaluation method are warranted.
Abstract
Purpose: Triple negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer. However, we have often experienced that triple positive breast cancer (TPBC) shows more aggressive clinical features than TNBC. In this retrospective study, we aimed to examine the differences in clinical courses between TNBC and TPBC. Methods: Using medical records and clinical data, we selected patients with breast cancer who met the criteria for the two groups, TNBC and TPBC, based on the expression or absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). We then compared these groups with respect to clinical and pathological variables, such as patient age at diagnosis, TNM stage, number of tumors, involvement of resection margin, operation methods, histologic grade (HG), nuclear grade (NG), and lymphatic invasion (LI). We also compared the disease-free (DFS) and overall survival (OS) outcomes between the groups. Results: Seventy patients with TNBC and 91 with TPBC were identified among a total of 628 patients. In univariate analysis, TPBC was significantly more frequently associated with lower HG (p=0.001), lower NG (p=0.003), LI (p=0.001), and a Ki-67 index ≤20% (p<0.001). In multivariate analysis, a lower Ki-67 index (p=0.031) and LI (p=0.022) were identified as significant and independent factors contributing to DFS. In a survival analysis over time, the TPBC showed a worse OS than TNBC 5 years post-treatment for breast cancer. Consequently, the TPBC group had definite worse 10-year DFS (p=0.012) and showed relatively lower OS rate (p=0.058), than the TNBC group. Conclusion: Our results demonstrate considerable differences in long-term post-treatment survival of patients with TPBC and TNBC. Further studies to determine the proper management of both types of breast cancer and an accurate prognostic evaluation method are warranted.
참고문헌 (27)
- Kamdje AHN, "Signaling pathways in breast cancer : therapeutic targeting of the microenvironment", Cell Signal, 26, pp.2843~2856 (2014)
- The cancer genome atlas network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
- Clark GM, "Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer", J Clin Oncol, 2, pp.1102~1109 (1984)
- Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
- Konecny G, "Quantitative association between HER-2", neu and steroid hormone receptors in hormone receptor-positive primary breast cancer, 2003, pp.95, 142~153
- Shin HY, "The effect of mechanical ventilation tidal volume during pneumoperitoneum on shoulder pain after a laparoscopic appendectomy", Surg Endosc, 24, pp.2002~2007 (2010)
- Park S, "Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry", Breast, 21, pp.50~57 (2012)
- Eroles P, "Molecular biology in breast cancer : intrinsic subtypes and signaling pathways", Cancer Treat Rev, 38, pp.698~707 (2012)
- Prat A, "Clinical implications of the intrinsic molecular subtypes of breast cancer", Breast, 24, pp.S26~35 (2015)
- Filipits M, "The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer", Clin Cancer Res, 20, pp.1298~1305 (2014)
- Vaz-Luis I, "Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the national comprehensive cancer network : a prospective cohort study", Breast Cancer Res, 14, pp.R129~ (2012)
- Perez EA, "Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31", J Clin Oncol, 29, pp.3366~3373 (2011)
- Houston SJ, "Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer", Br J Cancer, 79, pp.1220~1226 (1999)
- Andrulis IL, "neu", erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto breast cancer study group, 1998, pp.16, 1340~1349
- Han-Sung Kim, "Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer", Journal of Breast Cancer, 15(4), pp.401~406 (2012), 한국유방암학회[DOI]
- 박경미, "Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer", Journal of Breast Cancer, 14(4), pp.276~282 (2011), 한국유방암학회
- Goldhirsch A, "Thresholds for therapies : highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009", Ann Oncol, 20, pp.1319~1329 (2009)
- Viani GA, "Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer : a meta-analysis of published randomized trials", BMC Cancer, 7, pp.153~ (2007)
- Goss PE, "Extending aromatase-inhibitor adjuvant therapy to 10 years", N Engl J Med, 375, pp.209~219 (2016)
- Onitilo AA, "Breast cancer subtypes based on ER", PR and Her2 expression : comparison of clinicopathologic features and survival, 2009, pp.7, 4~13
- Negi P, "Survival of triple negative versus triple positive breast cancers : comparison and contrast", Asian Pac J Cancer Prev, 17, pp.3911~3916 (2016)
- Kollias J, "Early-onset breast cancer-histopathological and prognostic considerations", Br J Cancer, 75, pp.1318~1323 (1997)
- Jack RH, "Differences in breast cancer hormone receptor status in ethnic groups : a London population", Eur J Cancer, 49, pp.696~702 (2013)
- Inwald EC, "Ki-67 is a prognostic parameter in breast cancer patients : results of a large population-based cohort of a cancer registry", Breast Cancer Res Treat, 139, pp.539~552 (2013)
- Hashmi AA, "Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients", World J Surg Oncol, 16, pp.1~ (2018)
- Bilalovic N, "The Bcl-2 protein : a prognostic indicator strongly related to ER and PR in breast cancer", Bosn J Basic Med Sci, 4, pp.5~12 (2004)
- Thomadaki H, "Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer", Cancer Lett, 247, pp.48~55 (2007)